New cancer treatment shows promise by lowering testosterone

Cytomid 250, a promising new cancer drug, has been shown to slow or inhibit cancer cell growth by lowering testosterone levels in men Manufactured by renowned pharmaceutical company Grantpharmacy, Cytomid 250 may give patients a fighting testosterone cancer like prostate has new hope cancer.

Grantpharmacy principal investigator Dr John McCarthy said: "Early clinical trials have shown that Cytomid 250 can significantly lower testosterone levels in men, starving cancer cells of the hormone they need to grow and spread.